Like all therapeutics, cancer chemotherapy began as a largely emperical effort with a major emphasis on the interplay between serendipity and screening. The first major point I would like to make in this presentation is that a scientific base for cancer chemotherapy and for the construction of clinical trials has developed rapidly in the past five to 15 years. Basic research on the nature of the neoplastic cell has provided an increasing number of leads with respect to therapeutic targets exploitable by chemotherapy and immunotherapy (Fig. 1). The sciences of pharmacology and its subsets and of cytokinetics and biostatistics, uhich some refer to as “bridging sciences”, now impinge daily and importantly on the development and application of chemotherapeutic programs to man (Fig. 1). I would like to cite one important recent example that relates to structure activity studies.
KeywordsOsteogenic Sarcoma Combination Chemotherapy Complete Remission Rate Embryonal Rhabdomyosarcoma Overt Metastasis
Unable to display preview. Download preview PDF.
- 1.Di Marco, A., & Lenaz, L. Daunomycin and Adriamycin. In Cancer Medicine, Eds. J.F. Holland and E. Frei III, Lea & Febiger, Philadelphia, 1973, pp. 826–835.Google Scholar
- 2.Blum, R.H. & Carter S.K. A new cancer drug with significant clinical activity. Ann. Internal Med. 80, 249–259, 1974.Google Scholar
- 4.Skipper, H.E., Schabel, F.M. Jr. Quantitative and cytokinetic studies in experimental tumor models. In Cancer Medicine, Eds. J.F. Holland, E. Frei III, Lea & Febiger, Philadelphia, 1973, pp. 629–650.Google Scholar
- 5.Hakala, M.T. Transport of antineoplastic agents. In Antineoplastic and Immunosuppressive Agents. Chapter 13, pp. 240–269, 1974.Google Scholar
- 12.Canellos, G.P., Taylor, S.G. III., Band, P. & Pocock, S. Combination chemotherapy for advanced breast cancer: randomized comparison with single drug therapy. Prox. XI Intern. Cancer Congress 3:596, 1974 (abstr.)Google Scholar
- 14.Sartorelli, A.C. Combination chemotherapy. Cancer Medicine, Eds. J.F. Holland and E. Frei III, Lea & Febiger, Philadelphia, 1973, pp. 706–716, 1973.Google Scholar
- 17.Skarin, A., Rosenthal, D., Moloney, W. & Frei, E.III. Treatment of advanced non-Hodgkin’s lymphoma (NHL) with bleomycin (B), adriamycin (A), cyclophosphamide (C) and vincristine (O) and prednisone (P)(BAC0P), AACR/ASCO Proceedings 15:133, 1974.Google Scholar
- 18.Gottlieb, J., Baker, L.H., O’Brien, R.M. et al. Adriamycin used alone and in combination in soft tissue and bone sarcomas. Cancer Chemotherapy Reports (In press).Google Scholar
- 19.Frei, E. III & Freireich, E.J. Progress and perspective in the chemotherapy of acute leukemia. Advances Chemother. 2:269, 1965.Google Scholar
- 20.Ansfield, F.J. A randomized phase III study of four dosaoes reoimens of 5-fluorouracil — A preliminary report. 11th Annual Meeting of the American Society of Clinical Oncology, Abstract 1014, p. 224, 1975.Google Scholar
- 21.Sallan, S., Zinberg, N., Frei, E, III. Oral delta-9-tetrahydrocannabinol (THC) in the prevention of vomiting (V) associated with cancer chemotherapy (CC) 66th Annual Meeting of the American Association for Cancer Research, Abstract 575, p. 144, 1975.Google Scholar